ERADICATE Hp - Treating Helicobacter Pylori With RHB-105

This is a, randomized, double-blind, placebo-controlled study of RHB-105 in adult subjects
complaining of epigastric discomfort that have been screened and found to be positive for H.
pylori infection via 13C Urea Breath Test (UBT) and either fecal antigen test or CLO test.

Eligible subjects will be randomized in a ratio of 1:2 between placebo arm (n=30) and the
active arm (RHB-105) (n=60). Subjects will receive study drug for 14 consecutive days.
Eradication of H. pylori infection will be determined based on 13C UBT conducted between 28
to 56 days after completion of study drug therapy.

Subjects will be unblinded upon 13C UBT analysis. This will provide timely active therapy to
all subjects enrolled in this study. Subjects in the placebo arm will be entitled to receive
standard-of-care as prescribed by the treating physician following un-blinding.

Eradication failures (13C UBT-positive) in the active study drug arm will undergo upper
endoscopy with sampling for culture and sensitivity testing (to rifabutin, amoxicillin,
clarithromycin, and metronidazole). Culture and sensitivity directed therapy as prescribed
by the treating physician will be offered to these subjects.

Inclusion Criteria:

1. Be ≥18 years of age and ≤ 65 years

2. Have symptoms consistent with dyspepsia of at least two weeks duration (defined as
recurrent pain or discomfort centered in the upper abdomen, often with a relation to
meals)

3. Be positive for H. pylori by 13C Urea Breath Test (UBT) and also by fecal antigen
test

4. Be informed of the nature of the study and provide written informed consent before
any study specific procedures are performed (or have a legally authorized
representative sign consent)

Exclusion Criteria:

1. Have alarm symptoms/signs (including unexplained anemia [iron deficiency), melena /
hematemesis, anorexia, dysphagia, jaundice, weight loss)

2. Have taken antibiotics in the 4 weeks prior to screening

3. Have taken bismuth containing medications such as peptobismol in the 4 weeks prior to
screening

4. Have a history of any previous esophageal or gastric surgery, except for simple
closure of perforated ulcer

5. Have a history of gastric outlet obstruction

6. Have a history of hypersecretory state such as Zollinger-Ellison Syndrome

7. Have a history of gastric cancer

8. Have the presence of active gastric and duodenal ulcers or presence of 3 or more
active ulcers